# Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

> **NCT00993863** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 201 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** ADL5859 30 mg
- **DRUG:** ADL5859 100 mg
- **DRUG:** ADL5859 200 mg
- **DRUG:** ibuprofen 400 mg

## Key facts

- **NCT ID:** NCT00993863
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2015-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993863, "Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00993863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*